Definitive Healthcare Corp. (DH) Analyst Forecast
Revenue and earnings estimates published by analysts covering Definitive Healthcare Corp. (DH), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Definitive Healthcare Corp., analysts forecast revenue falling from $251.52T in 2023 to $221.97T in 2028; the average estimate for 2028 earnings per share is $0.18; with published estimates ranging from $0.18 to $0.19; 10 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD millions)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Definitive Healthcare Corp. (DH) forecast — frequently asked questions
What is the analyst price target for Definitive Healthcare Corp.?
Analysts covering Definitive Healthcare Corp. (DH) have a consensus price target of $1.20, 11.1% above the current price of $1.08. Published targets range from $1.00 to $1.50. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Definitive Healthcare Corp.'s earnings?
The average analyst estimate for Definitive Healthcare Corp. (DH) earnings per share in 2028 is 0.18, with individual estimates between 0.18 and 0.19.
How much revenue is Definitive Healthcare Corp. expected to make?
Analysts forecast Definitive Healthcare Corp. (DH) revenue of $221.97T in 2028, based on 2 published estimates.
How many analysts cover DH?
10 analysts contribute estimates for Definitive Healthcare Corp. (DH). Thin coverage makes an average less reliable.
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.